[Orient Paper, Inc. Science Park, Juli Road, Xushui County, Baoding City Hebei Province, P.R. China 072550 June 24, 2014 VIA EDGAR AND EMAIL 100 F Street NE Attention: Anne Nguyen Parker, Branch Chief Norman von Holtzendorff, Senior Counsel Re: Orient Paper, Inc. File No. Ladies and Gentlemen: · · · Please contact Jack I. Kantrowitz of DLA Piper LLP (US),]
[Orient Paper, Inc. Science Park, Juli Road, Xushui County, Baoding City Hebei Province, P.R. China 072550 June 24, 2014 VIA EDGAR AND EMAIL 100 F Street NE Attention: Anne Nguyen Parker, Branch Chief Norman von Holtzendorff, Senior Counsel Re: Orient Paper, Inc. File No. Ladies and Gentlemen: · · · Please contact Jack I. Kantrowitz of DLA Piper LLP (US),]
[Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) -- Collaborating with World Health Organization and Intravacc to Develop sIPV in line with mission to secure a lasting polio-free world, free of all paralytic polio disease Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) Collaborating] [Sinovac to Host Conference Call to Report First Quarter 2014 Unaudited Financial Results BEIJING, May 12, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2014, after market closes on Wednesday, May 21, 2014 EDT. The Company] [Sinovac Reports Unaudited First Quarter 2014 Financial Results -- -Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT Sinovac Reports Unaudited First Quarter 2014 Financial Results - Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT - BEIJING, May 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products] []
[Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) -- Collaborating with World Health Organization and Intravacc to Develop sIPV in line with mission to secure a lasting polio-free world, free of all paralytic polio disease Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) Collaborating] [Sinovac to Host Conference Call to Report First Quarter 2014 Unaudited Financial Results BEIJING, May 12, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2014, after market closes on Wednesday, May 21, 2014 EDT. The Company] [Sinovac Reports Unaudited First Quarter 2014 Financial Results -- -Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT Sinovac Reports Unaudited First Quarter 2014 Financial Results - Conference call scheduled for Thursday, May 22, 2014 at 8:00 AM EDT - BEIJING, May 21, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products] []
[Index to consolidated financial statements Use these links to rapidly review the document PROSPECTUS 7,315,000 American Depositary Shares Xunlei Limited Representing 36,575,000 common shares This is an initial public offering of American Depositary Shares, or ADSs, of Xunlei Limited, or Xunlei. We are offering 7,315,000 ADSs. Each ADS represents five common shares, par value US$0.00025 per share. We have received]
[Index to consolidated financial statements Use these links to rapidly review the document PROSPECTUS 7,315,000 American Depositary Shares Xunlei Limited Representing 36,575,000 common shares This is an initial public offering of American Depositary Shares, or ADSs, of Xunlei Limited, or Xunlei. We are offering 7,315,000 ADSs. Each ADS represents five common shares, par value US$0.00025 per share. We have received]
